Holen Sie sich die Stockscreener-App
14.98
1.54%
0.2616
Biohaven Ltd Aktie (BHVN) Neueste Nachrichten
BHVN Stock Builds Momentum Ahead Of Multiple H2 2026 Clinical Data Readouts - Stocktwits
BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout - Stocktwits
Biohaven Pharma stock falls after RBC Capital downgrade By Investing.com - Investing.com India
Biohaven Stock Seen Range-Bound as Near-Term Catalysts Fade, RBC Says - marketscreener.com
Biohaven stock downgraded at RBC Capital Markets (BHVN:NYSE) - Seeking Alpha
Biohaven Pharma stock falls after RBC Capital downgrade - Investing.com
BHVN Downgraded by RBC Capital -- Price Target Lowered to $19.00 - GuruFocus
RBC Downgrades Biohaven to Sector Perform From Outperform, Cuts Price Target to $19 From $23, Keeps Speculative Risk - marketscreener.com
Why is Biohaven Pharmaceutical stock sliding today? By Investing.com - Investing.com Canada
RBC Capital downgrades Biohaven Pharma stock rating on valuation By Investing.com - Investing.com Canada
Did Biohaven’s Kv7 Deal With SK Biopharmaceuticals Just Reshape BHVN’s Risk And Funding Profile? - simplywall.st
Biohaven (BHVN) Cashes In On Its Biggest Epilepsy Bet - Yahoo Finance
With an ion the bottom line, Biohaven signs SK epilepsy deal - BioWorld News
Biohaven (BHVN) Is Up 11.3% After Out-Licensing Kv7 Platform To SK Biopharm For Up To $795M - webull.com
Is Biohaven (BHVN) A Bargain On Its SK Biopharma Licensing Deal? - simplywall.st
Precision Trading with Biohaven Ltd. (BHVN) Risk Zones - Stock Traders Daily
Why Biohaven Stock Was Rocking the Market This Week - Yahoo Finance
Biohaven advances key drug trials and secures $350M deal with SK Biopharmaceuticals - Pluang
Biohaven: Sale Of Opakalim Rights To SK Biopharmaceuticals Makes Sense On Many Levels - Seeking Alpha
BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program - Yahoo Finance
Why Biohaven Ltd. (BHVN) Stock Is Up Today - Quiver Quantitative
Biohaven Ltd. And SK Biopharmaceuticals Co., Ltd. Enter Into Global Licensing Agreement For Kv7 Ion Channel Platform And Opakalim - marketscreener.com
Biohaven stock surges 7% on SK Biopharmaceuticals deal By Investing.com - Investing.com Australia
Biohaven licenses Kv7 epilepsy platform to SK Biopharma for up to $795M - StreetInsider
SK Bio taps up Biohaven for Kv7 platform and epilepsy drug in USD 795m deal - AllSci
Biohaven stock surges 7% on SK Biopharmaceuticals deal - Investing.com
Biohaven (NYSE: BHVN) offloads epilepsy drug costs in rich global licensing pact - Stock Titan
Biohaven, Yale win $4M judgment in trade secret case By Investing.com - Investing.com Nigeria
Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University - PR Newswire
Biohaven’s epilepsy drug deal could bring $400 million in cash from SK Biopharmaceuticals - Stock Titan
Is Biohaven (BHVN) Undervalued Following Its Latest Earnings Loss Improvement? - Sahm
Why Biohaven (BHVN) Is Down 9.1% After Reporting Narrower Q2 and H1 Net Losses - Sahm
Price to earnings forward of Biohaven Ltd. – NYSE:BHVN - TradingView
HC Wainwright Decreases Earnings Estimates for Biohaven - MarketBeat
NewEdge Wealth LLC Invests $3.66 Million in Biohaven Ltd. $BHVN - MarketBeat
Biohaven Ltd. (NYSE:BHVN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Piper Sandler Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Biohaven (BHVN) Pulls Back 1.4% as Shares Approach Key $13.91 Support ZoneChannel Breakout - vinanet.vn
Biohaven Ltd. $BHVN Shares Bought by Quantinno Capital Management LP - MarketBeat
Is Biohaven’s Narrowing Losses and AI Board Hire Altering The Investment Case For Biohaven (BHVN)? - Sahm
Biohaven (BHVN) Could Be 73% Undervalued As Regeneron Deal Expands - simplywall.st
Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline? - Yahoo Finance
Woodline Partners (BHVN) discloses 5.1% beneficial stake in Biohaven - Stock Titan
Renaissance Technologies LLC Acquires New Position in Biohaven Ltd. $BHVN - MarketBeat
Bank of America Securities Reaffirms Their Buy Rating on Biohaven Ltd. (BHVN) - The Globe and Mail
Biohaven 2Q Loss/Shr 91c >BHVN - Moomoo
Biohaven Ltd. (BHVN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Biohaven Pharma stock price target raised to $23 by RBC Capital - Investing.com Nigeria
Biohaven Supported by Multiple Pipeline Catalysts, Cash Runway Into 2027, RBC Says - Moomoo
Biohaven Ltd. (BHVN) Stock Analysis: Exploring The 57.73% Potential Upside For Investors - DirectorsTalk Interviews
Biohaven (BHVN) Holds Near Key Support After Modest PullbackPre-Earnings Momentum - vinanet.vn
Biohaven Ltd. (BHVN) stock price, news, quote and history - Yahoo Finance Australia
Biohaven (NYSE:BHVN) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Biohaven narrows Q2 losses 29%, initiates pivotal Graves' trial - scanx.trade
Biohaven Ltd. Announces Q2 2026 Financial Results Highlighting Reduced Losses and R&D Spending - Kalkine Media
Biohaven reports Q2 2026 net loss of $137.3M, cash and marketable securities $267.9M - TradingView
Biohaven (NYSE: BHVN) reports $267.8M H1 2026 loss and $267.9M in liquidity - Stock Titan
Biohaven Ltd. reports results for the quarter ended June 30Earnings Summary - TradingView
Biohaven Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Biohaven Ltd. $BHVN Shares Purchased by The Manufacturers Life Insurance Company - MarketBeat
0.71%
2.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):